JP Morgan increased its holdings of Guangzhou Baiyunshan Pharmaceutical Holdings (00874) by approximately 143,900 shares at a price of around 16.89 Hong Kong dollars per share.

18:58 02/04/2026

On March 30th, HSBC increased its holdings of Baiyunshan (00874) by 143,924 shares, with a price of 16.8915 Hong Kong dollars per share, for a total amount of approximately 2.4311 million Hong Kong dollars.

Hong Kong Stock Exchange latest data shows that on March 30, JP Morgan increased its holdings of Guangzhou Baiyunshan Pharmaceutical Holdings (00874) by 143,924 shares, with a price of 16.8915 Hong Kong dollars per share, for a total amount of approximately 2.4311 million Hong Kong dollars. After the increase, the latest number of shares held is approximately 19.9102 million shares, with a latest shareholding ratio of 9.05%.

China Securities Co., Ltd. reviews the A-share market in the first quarter of 2026: This bull market is more forward-looking in terms of regulation and will take timely measures to address overheated trading.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.